Our Pricing

The Science Behind What Does Mounjaro Do

Published on: June 03, 2026

Understanding what does Mounjaro do for weight loss UK requires examining its unique dual-hormone mechanism. As the first GIP/GLP-1 receptor agonist licensed by the MHRA, Mounjaro (tirzepatide) activates two metabolic pathways simultaneously, producing significantly greater weight reduction than single-pathway alternatives in clinical trials.

What Does Mounjaro Do: The Dual-Hormone Mechanism

Mounjaro contains tirzepatide, which activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously [1]. This dual action distinguishes it from semaglutide-based treatments like Wegovy and Saxenda, which target only GLP-1 receptors. By engaging both pathways, tirzepatide enhances insulin secretion more effectively whilst suppressing glucagon release and slowing gastric emptying.

The GIP component specifically targets adipose tissue metabolism and may reduce inflammation associated with obesity [1]. Meanwhile, the GLP-1 action reduces appetite through hypothalamic signalling and improves glycaemic control. This combined mechanism explains why clinical trials demonstrated superior weight loss outcomes compared to GLP-1-only medications.

How Tirzepatide Affects Appetite and Metabolism

Mounjaro works by mimicking natural gut hormones released after eating. The medication signals to your brain that you feel fuller for longer, reducing hunger between meals and decreasing overall calorie intake [2]. Simultaneously, it slows the rate at which food leaves your stomach, prolonging satiety after eating.

At the metabolic level, tirzepatide improves how your body processes glucose and fat. Patients typically notice reduced cravings for high-calorie foods within the first few weeks of treatment, though individual responses vary based on baseline metabolism and adherence to lifestyle modifications.

Clinical Trial Results: What Does Mounjaro Do in Real-World Studies

The SURPASS-3 trial demonstrated that adults taking the 15mg maintenance dose of Mounjaro achieved an average 22.5% body weight reduction over 72 weeks [1]. This represents approximately 20-25kg weight loss for a 100kg individual, though results vary based on starting weight and lifestyle factors. Importantly, 91% of participants achieved at least 5% weight loss, and 57% achieved 20% or greater reduction.

Comparative data from the SURMOUNT-2 trial showed tirzepatide outperformed placebo by an average of 15.7 percentage points in weight reduction at 72 weeks [3]. These outcomes exceeded those observed in semaglutide trials, where the highest doses produced average reductions of 14.9% over similar timeframes [4]. All participants in these studies combined medication with reduced-calorie diet and increased physical activity.

Beyond weight loss, clinical trials documented improvements in cardiovascular risk markers. Patients experienced average reductions in systolic blood pressure of 7-10 mmHg, decreased triglyceride levels, and improved HbA1c measurements even in those without diabetes [3]. These metabolic benefits contribute to overall health improvements beyond the number on the scale.

What Does Mounjaro Do Compared to Other Weight Loss Treatments

When comparing efficacy, Mounjaro's dual-receptor mechanism produces measurably greater weight reduction than single-pathway alternatives available through UK pharmacies. Wegovy (semaglutide) demonstrated average weight loss of 14.9% in the STEP 1 trial, whilst Saxenda (liraglutide) achieved approximately 8% in the SCALE trial [2][4]. Orlistat-based treatments like Xenical typically produce 5-10% weight loss when combined with dietary changes.

The injection frequency differs across treatments. Mounjaro and Wegovy require once-weekly subcutaneous injections, whilst Saxenda requires daily administration. Oral options like Wegovy tablets and Orlistat capsules appeal to patients who prefer to avoid injections, though injectable GLP-1 medications generally demonstrate superior weight loss outcomes in head-to-head comparisons.

Side effect profiles vary between treatments. GLP-1 and dual-agonist medications commonly cause gastrointestinal symptoms including nausea, diarrhoea, and constipation, particularly during dose escalation [1][2]. Orlistat produces different side effects related to fat malabsorption. Your UK prescriber will assess your medical history, current medications, and treatment preferences to determine the most appropriate option.

Choosing Between Injectable and Oral Weight Loss Medications

Injectable treatments like Mounjaro demonstrate higher efficacy in clinical trials but require comfort with self-administration. The KwikPen delivery system uses a small needle similar to insulin pens, and most patients report minimal discomfort after the first few injections. Weekly dosing provides convenience compared to daily injections.

Oral alternatives including Wegovy tablets and Orlistat capsules suit patients who cannot or prefer not to inject. Whilst oral semaglutide shows promising results, orlistat-based treatments work through a different mechanism (blocking fat absorption) and typically produce more modest weight loss. All prescription options available at Cured Pharmacy require clinical assessment by a UK prescriber to ensure safety and appropriateness.

What Does Mounjaro Do for Different Patient Groups

Mounjaro is licensed in the UK for adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension or type 2 diabetes [1]. The MHRA approval followed extensive clinical trials demonstrating safety and efficacy across diverse patient populations, including those with varying baseline weights and metabolic conditions.

Clinical trial data shows consistent efficacy across age groups, though patients over 65 were underrepresented in initial studies. Individuals with higher baseline BMI often experience greater absolute weight loss, whilst those closer to the 27 kg/m² threshold may see smaller numerical reductions but significant improvements in metabolic markers [3]. Response rates remain high across demographics when medication is combined with lifestyle modifications.

Certain patient groups cannot take Mounjaro due to contraindications. These include individuals with personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, or pregnancy. Your UK prescriber will review your complete medical history during the online consultation to ensure tirzepatide is safe and appropriate for your circumstances.

Understanding What Mounjaro Does: Dosing and Treatment Timeline

Mounjaro treatment begins with a 2.5mg dose administered once weekly for four weeks [1]. This initial dose allows your body to adjust to the medication whilst minimising gastrointestinal side effects. Your prescriber will then increase the dose to 5mg weekly, with further escalations every four weeks as tolerated, up to a maximum maintenance dose of 15mg weekly depending on your response and tolerability.

Most patients begin noticing appetite reduction within the first two weeks, though significant weight loss typically becomes apparent after 8-12 weeks of treatment. The dose escalation schedule balances efficacy with tolerability—rushing to higher doses increases the likelihood of nausea and vomiting that may lead to treatment discontinuation. Clinical trials used this gradual titration approach to achieve the published weight loss outcomes.

Treatment duration varies based on individual goals and response. Clinical trials evaluated tirzepatide over 72 weeks, and many patients require ongoing treatment to maintain weight loss [3]. Discontinuing Mounjaro often results in gradual weight regain, similar to other weight management medications. Your UK prescriber will monitor your progress through follow-up consultations and adjust treatment plans as needed.

What to Expect During Your First Month on Mounjaro

During the initial 2.5mg dose phase, you may experience mild nausea, reduced appetite, and occasional digestive changes as your body adjusts to the medication. These effects typically diminish within 2-3 weeks. Eating smaller, more frequent meals and avoiding high-fat foods can help minimise discomfort during this adjustment period.

Weight loss during the first month is typically modest—most patients lose 1-3kg whilst on the starter dose. This gradual beginning allows sustainable habit changes and reduces the metabolic stress of rapid weight loss. Significant results accumulate over subsequent months as doses increase and lifestyle modifications reinforce the medication's appetite-suppressing effects.

What Does Mounjaro Do: Managing Side Effects and Optimising Results

The most common side effects reported in clinical trials include nausea (affecting up to 30% of patients), diarrhoea, constipation, abdominal discomfort, and reduced appetite [1][2]. These gastrointestinal symptoms typically peak during dose escalation periods and decrease in intensity as your body adapts. Severe or persistent symptoms warrant consultation with your prescriber, who may adjust your dosing schedule.

Practical strategies can minimise side effects whilst maximising weight loss outcomes. Eat slowly and stop when comfortably satisfied rather than completely full. Choose protein-rich, fibre-containing foods that promote satiety without triggering nausea. Stay well-hydrated, particularly if experiencing vomiting or diarrhoea. Avoid lying down immediately after eating, as this can worsen reflux symptoms some patients experience on GLP-1 medications.

Combining Mounjaro with lifestyle modifications enhances results beyond medication alone. Clinical trial participants who achieved the greatest weight loss followed reduced-calorie diets and increased physical activity to at least 150 minutes weekly [3]. Your treatment plan from Cured Pharmacy includes guidance on sustainable dietary changes and activity goals appropriate for your fitness level. Regular monitoring through follow-up consultations ensures you progress safely towards your weight management objectives.

When to Contact Your Prescriber About Side Effects

Seek immediate medical attention if you experience severe abdominal pain that doesn't resolve, persistent vomiting preventing fluid intake, signs of pancreatitis (severe upper abdominal pain radiating to the back), or symptoms of thyroid tumours (lump in neck, difficulty swallowing, persistent hoarseness). These serious side effects are rare but require prompt evaluation.

Contact your prescriber for guidance if you experience side effects that interfere with daily activities, symptoms that persist beyond the first few weeks at a new dose, or if you're not seeing expected weight loss after 12-16 weeks on therapeutic doses. Dose adjustments or alternative treatments may be appropriate based on your individual response and tolerability.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. https://doi.org/10.1016/j.molmet.2020.101102 [accessed 13 August 2026]
3. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2023). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 29(10), 2473–2480. https://doi.org/10.1038/s41591-023-02532-4 [accessed 13 August 2026]
4. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary. Weight loss outcomes depend on multiple factors including baseline weight, adherence to lifestyle modifications, and individual metabolic response. Mounjaro is a prescription-only medicine licensed by the MHRA for weight management in eligible adults.